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lines. METHODS: Data from the National Ambulatory
Medical Care Survey (NAMCS) 1997 was utilized. Pa-
tients with principal diagnosis of otitis media with age
less than or equal to 12 years were analyzed using multi-
ple linear and binomial logit regression models. Appro-
priate antibiotics are defined as those that are recom-
mended by the guidelines. The average wholesale price of
recommended antibiotics was compared with the inap-
propriate antibiotics prescribed. The dosage of antibiot-
ics was confirmed by the IMS health and the advice of a
practicing Otolaryngologist. Antibiotics cost was calcu-
lated by using the Red Book 1997 and 1998. The
weighted average method was used to calculate the aver-
age wholesale price of the various quantity packages and
dosage forms. This study utilized the methodology of re-
lating a secondary database to an outside source (Red
Book) to calculate the cost. RESULTS: The average cost
of a course of appropriate antibiotic (penicillin and its de-
rivatives) was found to be $8.07, compared to $69.56 for
expensive antibiotics (difference  $61.49). Children less
than four years of age were prescribed more expensive
antibiotics (R2  0.287). Pediatricians, and Otolaryngol-
ogists prescribed appropriate and less expensive antibiot-
ics than other family physicians (R2  0.144). There was
no relationship between the physician’s specialty and pa-
tient’s age for inappropriate antibiotics prescribing (R2 
0.345). CONCLUSIONS: Adhering to the guidelines and
prescribing of appropriate antibiotics appears to save
cost. Inappropriate prescribing of antibiotics for otitis
media should be addressed more explicitly in general
practice.
PEE6
COST-EFFECTIVENESS OF ARTIFICIAL SKIN 
SUBSTITUTE VS ALLOGRAFT FOR
BURN PATIENTS
Bron MS, Hay J
University of Southern California, Los Angeles, CA, USA
INTRODUCTION: Healing after a burn injury requires
a temporary wound cover until the skin epithelium heals.
Traditional wound covering, human cadaver allograft
(HCA), is expensive, and limited by availability. OBJEC-
TIVE: To determine if artificial skin substitute (Tran-
scyte) wound cover is cost-effective for temporary wound
coverage in patients with major total body surface
(TBSA) burns. METHODS: Incremental cost per quality
adjusted life year (QALY) in 2000 US dollars is estimated
assuming a base case adult patient who has 40% TBSA
burn with no inhalation injury, complications, or facial
burn followed for one year after HCA or Transcyte pro-
cedure. A societal perspective is used. Utilities were sur-
veyed from burn-unit hospital employees. Other vari-
ables are taken from literature. RESULTS: Under the
base case, Transcyte saves $3600 over HCA, and adds
0.04 QALYs. Quality of life was significantly greater in
the Transcyte group (0.54, 95% CI  0.48–0.59) vs.
HCA group (0.65, 95% CI  0.57–0.74, p  0.04) while
in the hospital, but not significantly different while recov-
ering at home, after recovery, and at work. The incre-
mental QALY of Transcyte minus HCA must be 0.07
in order for the ICER to reach a threshold of $50,000.
Sensitivity analysis shows that a 33% increase in Tran-
scyte price will reach the threshold ICER of $50,000. In
addition, this model is highly sensitive to utility at work;
a 22% decrease of at-work utility with Transcyte will re-
sult in an ICER greater than $50,000. CONCLUSIONS:
The results show that use of Transcyte as a temporary
wound covering for 40% TBSA burns is a dominant
strategy relative to standard HCA. Use of this artificial
skin results in cost savings, due to faster healing and less
operation room time. A gain in QALYs is seen with
Transcyte, due to less scarring and pain during the heal-
ing process.
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OBJECTIVE: To compare the total, drug, and medical
care costs of common practice and best practice manage-
ment of primary open-angle glaucoma (POAG). METH-
ODS: A Delphi panel of ophthalmologists specialized in
glaucoma management was convened in order to delin-
eate practice patterns representative of community physi-
cians (common practice), and to characterize the ideal or
optimal standards of care (best practice). A decision ana-
lytic approach was used to depict and economically
quantify the clinical sequelae under each scenario for
POAG patients initiated on medical therapy. Common
and best practice decision trees were developed for proto-
typic agents of the most commonly used first-line classes
of medications. Percentage likelihood of drug usage was
determined based upon physician consensus whereas
drug and surgical efficacy rates were determined based
upon a composite of published data. Typical drug dosing
regimens and number of medical visits, as determined by
physician consensus, were used to estimate the cost of
treatment. RESULTS: The total average annual cost of
treatment per eye was estimated at $733.85 for common
practice and $732.09 for best practice. Drug costs were
estimated at $358.66 for common practice and $341.38
for best practice. Costs of medical care were estimated at
$375.19 for common practice and $390.71 for best prac-
tice. Surgical costs comprised a larger proportion of med-
ical care costs in best practice as compared to common
practice (17.84% vs. 14.29%). In comparing best prac-
tice and common practice decision analyses, non-selective
beta-blockers were used less often whereas alpha-2 ago-
